Dr. Alicia Arnold and Dr. Priyanka Raval discuss first- and later-line treatment options for those with ER-positive, ...

Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® ...

How many, if any, cases of nervous system disorders have been reported because of A-C breast cancer chemotherapy? I'm 45 and had treatment at 39 and 40. I now experience a very exaggerated amount of ...

In 2004, the American Society of Clinical Oncology reported its evaluation of the use of aromatase inhibitors (AIs) in the adjuvant treatment of postmenopausal breast cancer. While the panel endorsed ...

Panelists discuss the SERENA-6 trial evaluating camizestrant, which uniquely enrolled patients with molecularly detected ESR1 ...

Repronovo announces first participant included in US phase 2 trial of RPN-001 to treat MALE INFERTILITY: Lausanne, Switzerland Wednesday, July 2, 2025, 14:00 Hrs [IST] ReproNovo, ...

RPN-001 is a novel orally administered aromatase inhibitor being developed for the treatment of infertility in men with low ...

HR-positive/HER2-negative is the most common subtype of breast cancer in women. HR-positive/HER2-negative metastatic breast ...

Research led by Samsung Medical Center finds breast cancer survivors exhibit an 8% lower risk of Alzheimer's dementia (AD) ...

Bone and Cancer Working Group has released a comprehensive review detailing the often under-recognized impact of modern anti-cancer treatments on bone health.

Future study designs evaluating cognitive dysfunction in patients on aromatase inhibitors should include a multifaceted approach of neuropsychiatric testing and neurological functional imaging.

Cite this: Cognitive Dysfunction in Postmenopausal Breast Cancer Patients on Aromatase Inhibitors - Medscape - Aug 01, 2011.